Abstract
Malignant pleural mesothelioma (MPM) is a highly aggressive neoplasm arising mainly in the pleural and with tendency to invasion to adjacent structures, such as chest wall, mediastinum and diaphragm. Lymph node metastasis and extension to other organs also can occur. Management is extremely difficult with a described median survival period of 9 to 17 months. Neoplastic extension and VEGF expression have direct relationship to prognosis.
Although computed tomography is the primary imaging modality for diagnosis, staging and follow – up of therapeutic response to MPM, functional techniques such as diffusion weighted imaging (DWI), dynamic contrast enhanced MR imaging (DCE – MRI), and 2-deoxy-2-[18F]fluoro-D-glucose-(FDG)-positron emission tomography-computed tomography (18FDG-PET/CT) allow better differentiation of benign versus malignant pleural disease, assessment of local infiltration of adjacent structures, whole body extension and monitoring therapeutic response. Because the importance of accurate staging, cell type and neoangiogenesis in the prognosis of this kind of tumors, some DWI, DCE and 18FDG-PET/CT related parameters have been related directly to good or poor outcome previous to applying antiangiogenic agents.
Functional MRI (DCE-MRI and DWI) and 18FDG-PET/CT have the potential to provide valuable information in the characterization of primary and metastatic chest wall tumors, but also in the differentiation of benign of malignant ones and therapeutic response monitorization.
In the next few lines we are going to review different aspects of MPM with special focus on functional techniques and its role in staging and assessment of therapeutic response and recurrence. Also functional imaging of other benign and malignant (non-MPM) diseases, which could be false positives, and chest wall tumors are discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- 18FDG-PET/CT:
-
2-deoxy-2-[18F]fluoro-D-glucose-(FDG)-positron emission tomography-computed tomography
- 18FDG:
-
2-deoxy-2-[18F]fluoro-D-glucose-(FDG)
- ADC:
-
Apparent diffusion coefficient
- Au/s:
-
Arbitrary units per second
- ChT:
-
Chemotherapy
- C peak :
-
Maximal contrast enhancement
- CT:
-
Computed tomography
- DCE-MRI:
-
Dynamic contrast enhanced magnetic resonance imaging
- DWI:
-
Diffusion weighted imaging
- EPP:
-
Extrapleural pneumonectomy
- FLASH:
-
Fast low angle shot
- FLT:
-
18Fluorine – labelled thymidine
- Gd-CM:
-
Gadolinium based contrast media
- IS:
-
Initial slope
- K el :
-
Elimination rate
- K ep :
-
Redistribution rate
- MPM:
-
Malignant pleural mesothelioma
- MRI:
-
Magnetic resonance imaging
- PDWI:
-
Proton density weighted imaging
- RT:
-
Radiation therapy
- SFTP:
-
Solitary fibrous tumor of the pleura
- SUV:
-
Standardized uptake value
- SUVmax :
-
Maximum standardized uptake value
- T1WI:
-
T1-weighted imaging
- T2WI:
-
T2-weighted imaging
- TGV:
-
Total glycolitic volume
- TIC:
-
Time intensity curve
- TNM:
-
Tumor, node, metastases staging system
- TrueFISP:
-
True fast imaging with steady-state precession
References
Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992;34:718–21. Epub 1992/07/01.
Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591–603. Epub 2005/10/14.
Wang ZJ, et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics. 2004;24:105–19. Epub 2004/01/20.
Carbone M, et al. The pathogenesis of mesothelioma. Semin Oncol. 2002;29:2–17. Epub 2002/02/12.
Sugarbaker DJ, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63; discussion −5. Epub 1998/12/31.
Tsao AS, et al. Malignant pleural mesothelioma. J Clin Oncol. 2009;27:2081–90. Epub 2009/03/04.
Edwards JG, et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer. 2001;85:863–8. Epub 2001/09/15.
Strizzi L, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001;193:468–75. Epub 2001/03/29.
Yamamuro M, et al. Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol. 2007;64:356–66. Epub 2007/10/24.
Zucali PA, Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer. 2006;42:2706–14. Epub 2006/09/23.
Basu S, et al. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment. Mol Imaging Biol. 2011;13:801–11. Epub 2010/12/08.
O’Brien ME, et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol. 2006;17:270–5. Epub 2005/12/01.
Vogelzang NJ. Standard therapy for the treatment of malignant pleural mesothelioma. Lung Cancer. 2005;50:S23–4. Epub 2005/11/18.
Vogelzang NJ, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44. Epub 2003/07/16.
Bonomo L, et al. Malignant pleural disease. Eur J Radiol. 2000;34:98–118. Epub 2000/06/30.
Hierholzer J, et al. MRI and CT in the differential diagnosis of pleural disease. Chest. 2000;118:604–9. Epub 2000/09/16.
Leung AN, et al. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol. 1990;154:487–92. Epub 1990/03/01.
Yildirim H, et al. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol. 2009;4:1480–4. Epub 2009/10/31.
Benard F, et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;114:713–22. Epub 1998/09/22.
Bury T, et al. Evaluation of pleural diseases with FDG-PET imaging: preliminary report. Thorax. 1997;52:187–9. Epub 1997/02/01.
Gerbaudo VH, et al. Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med. 2002;43:1144–9. Epub 2002/09/07.
Orki A, et al. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac Cardiovasc Surg. 2009;57:217–21. Epub 2009/08/12.
Fujimoto K. Usefulness of contrast-enhanced magnetic resonance imaging for evaluating solitary pulmonary nodules. Cancer Imaging. 2008;8:36–44. Epub 2008/03/12.
Sager S, et al. False positive (18)F-FDG-PET/CT findings in a patient with talc pleurodesis. Hell J Nucl Med. 2010;13:179–80. Epub 2010/09/03.
Coolen J, et al. Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging–initial experience. Radiology. 2012;263:884–92. Epub 2012/04/27.
Taouli B, et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology. 2009;251:398–407. Epub 2009/03/12.
Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology. 2010;254:47–66. Epub 2009/12/25.
Lyng H, et al. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med. 2000;43:828–36. Epub 2000/06/22.
Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995;108:1122–8. Epub 1995/10/01.
Heelan RT, et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol. 1999;172:1039–47. Epub 1999/12/10.
Marom EM, et al. The role of imaging in malignant pleural mesothelioma. Semin Oncol. 2002;29:26–35. Epub 2002/02/12.
Roach HD, et al. Asbestos: when the dust settles an imaging review of asbestos-related disease. Radiographics. 2002;22:S167–84. Epub 2002/10/12.
Gill RR, et al. Current trends in radiologic management of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21:111–20. Epub 2009/10/14.
Knuuttila A, et al. Evaluation of pleural disease using MR and CT. With special reference to malignant pleural mesothelioma. Acta Radiol. 2001;42:502–7. Epub 2001/09/13.
Gill RR, et al. Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes. AJR Am J Roentgenol. 2010;195:W125–30. Epub 2010/07/24.
Plathow C, et al. Quantitative analysis of lung and tumour mobility: comparison of two time-resolved MRI sequences. Br J Radiol. 2005;78:836–40. Epub 2005/08/20.
Gerbaudo VH, et al. Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma. Thorax. 2003;58:1077–82. Epub 2003/12/04.
Gerbaudo VH, Julius B. Anatomo-metabolic characteristics of atelectasis in F-18 FDG-PET/CT imaging. Eur J Radiol. 2007;64:401–5. Epub 2007/09/18.
Wilcox BE, et al. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer. 2009;10:244–8. Epub 2009/07/28.
Brix G, et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr. 1991;15:621–8. Epub 1991/07/01.
Giesel FL, et al. Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome. Chest. 2006;129:1570–6. Epub 2006/06/17.
Hatabu H, et al. Pulmonary perfusion: qualitative assessment with dynamic contrast-enhanced MRI using ultra-short TE and inversion recovery turbo FLASH. Magn Reson Med. 1996;36:503–8. Epub 1996/10/01.
Hatabu H, et al. Quantitative assessment of pulmonary perfusion with dynamic contrast-enhanced MRI. Magn Reson Med. 1999;42:1033–8. Epub 1999/11/26.
Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol. 2006;24:3293–8. Epub 2006/07/11.
Ohno Y, et al. Solitary pulmonary nodules: potential role of dynamic MR imaging in management initial experience. Radiology. 2002;224:503–11. Epub 2002/07/31.
Giesel FL, et al. Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34). Academic radiology. 2008;15:563–70. Epub 2008/04/22.
Tan C, et al. Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma. J Thorac Oncol. 2010;5:385–8. Epub 2010/01/21.
Veit-Haibach P, et al. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer. 2010;67:311–7. Epub 2009/06/02.
Pehlivan B, et al. Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma. Radiat Oncol. 2009;4:35. Epub 2009/09/18.
Mankoff DA, et al. PET imaging of cellular proliferation. Radiol Clin North Am. 2005;43:153–67. Epub 2005/02/08.
Lucignani G. PET imaging with hypoxia tracers: a must in radiation therapy. Eur J Nucl Med Mol Imaging. 2008;35:838–42. Epub 2008/02/12.
Basu S, Alavi A. Molecular imaging (PET) of brain tumors. Neuroimaging Clin North Am. 2009;19:625–46. Epub 2009/12/05.
Kawashima A, Libshitz HI. Malignant pleural mesothelioma: CT manifestations in 50 cases. AJR Am J Roentgenol. 1990;155:965–9. Epub 1990/11/01.
Sahin AA, et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT findings in 84 patients. AJR Am J Roentgenol. 1993;161:533–7. Epub 1993/09/01.
Schneider DB, et al. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2000;120:128–33. Epub 2000/07/08.
Maskell NA, Butland RJ. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax. 2003;58:ii8–17. Epub 2003/05/03.
Luna A, et al. Diffusion MRI outside the brain a case-based review and clinical applications. Heidelberg/New York: Springer-Verlag; 2012. Available from: http://dx.doi.org/10.1007/978-3-642-21052-5.
Davis SD, et al. MR imaging of pleural effusions. J Comput Assist Tomogr. 1990;14:192–8. Epub 1990/03/01.
Baysal T, et al. Diffusion-weighted MR imaging of pleural fluid: differentiation of transudative vs exudative pleural effusions. Eur Radiol. 2004;14:890–6. Epub 2003/08/09.
Inan N, et al. Diffusion-weighted MRI in the characterization of pleural effusions. Diagn Interv Radiol. 2009;15:13–8. Epub 2009/03/06.
Qureshi NR, Gleeson FV. Imaging of pleural disease. Clin Chest Med. 2006;27:193–213. Epub 2006/05/24.
Gill RR, et al. MR imaging of benign and malignant pleural disease. Magn Reson Imaging Clin North Am. 2008;16:319–39, x. Epub 2008/05/14.
Weber MA, et al. Asbestos-related pleural disease: value of dedicated magnetic resonance imaging techniques. Invest Radiol. 2004;39:554–64. Epub 2004/08/17.
Lorigan JG, Libshitz HI. MR imaging of malignant pleural mesothelioma. J Comput Assist Tomogr. 1989;13:617–20. Epub 1989/07/01.
Inaoka T, et al. Solitary fibrous tumor of the pleura: apparent diffusion coefficient (ADC) value and ADC map to predict malignant transformation. J Magn Reson Imaging. 2007;26:155–8. Epub 2007/07/31.
Rosado-de-Christenson ML, et al. From the archives of the AFIP: localized fibrous tumor of the pleura. Radiographics. 2003;23:759–83. Epub 2003/05/13.
Theros EG, Feigin DS. Pleural tumors and pulmonary tumors: differential diagnosis. Semin Roentgenol. 1977;12:239–47. Epub 1977/07/01.
Tateishi U, et al. Solitary fibrous tumor of the pleura: MR appearance and enhancement pattern. J Comput Assist Tomogr. 2002;26:174–9. Epub 2002/03/09.
Ginat DT, et al. Imaging features of solitary fibrous tumors. AJR Am J Roentgenol. 2011;196:487–95. Epub 2011/02/24.
Sahn SA. Malignancy metastatic to the pleura. Clin Chest Med. 1998;19:351–61. Epub 1998/07/01.
Henschke CI, et al. Pleural diseases: multimodality imaging and clinical management. Curr Probl Diagn Radiol. 1991;20:155–81. Epub 1991/09/01.
Shuman LS, Libshitz HI. Solid pleural manifestations of lymphoma. AJR Am J Roentgenol. 1984;142:269–73. Epub 1984/02/01.
Patz Jr EF, et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol. 1992;159:961–6. Epub 1992/11/11.
Falaschi F, et al. Comparison of computerized tomography and magnetic resonance in the assessment of benign and malignant pleural diseases. Radiol Med (Torino). 1996;92:713–8. Epub 1996/12/01. Confronto fra Tomografia Computerizzata e Risonanza Magnetica nella valutazione delle malattie pleuriche benigne e maligne.
Duysinx B, et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest. 2004;125:489–93. Epub 2004/02/11.
Kramer H, et al. PET for the evaluation of pleural thickening observed on CT. J Nucl Med. 2004;45:995–8. Epub 2004/06/08.
Tateishi U, et al. Chest wall tumors: radiologic findings and pathologic correlation: part 2. Malignant tumors. Radiographics. 2003;23(6):1491–508.
Nam SJ, et al. Imaging of primary chest wall tumors with radiologic-pathologic correlation.Radiographics. 2011;31(3):749–70.
O’Sullivan P, et al. Soft tissue tumours and mass-like lesions of the chest wall: a pictorial review of CT and MR findings. Br J Radiol. 2007;80(955):574–80.
Mullan CP, et al. Radiology of chest wall masses. AJR Am J Roentgenol. 2011;197(3):460–70.
Petermann D, et al. Value of positron emission tomography in full-thickness chest wall resections for malignancies. Interact Cardiovasc Thorac Surg. 2009;9(3):406–10.
Nishiyama Y, et al. Prediction of treatment outcomes in patients with chest wall sarcoma: evaluation with PET/CT. Jpn J Clin Oncol. 2012;42(10):912–8.
Costa FM, et al. Advanced magnetic resonance imaging techniques in the evaluation of musculoskeletal tumors. Radiol Clin North Am. 2011;49(6):1325–58, vii–viii.
Nagata S, et al. Diffusionweighted imaging of soft tissue tumors: usefulness of the apparent diffusion coefficient for differential diagnosis. Radiat Med. 2008;26(5):287–95.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Broncano, J., García-Velloso, M.J., Martin-Noguerol, T., Luna, A. (2014). Functional Imaging of Malignant Pleural Mesothelioma and other Pleural and Chest Wall Lesions. In: Luna, A., Vilanova, J., Hygino Da Cruz Jr., L., Rossi, S. (eds) Functional Imaging in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40582-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-40582-2_7
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-40581-5
Online ISBN: 978-3-642-40582-2
eBook Packages: MedicineMedicine (R0)